5.645

3.82% -0.245

Aardvark Therapeutics Inc (AARD)

Overview News Price History Discussions Forecast

Aardvark Therapeutics Inc stock is traded at $5.645, with a volume of 91,502. It is down -3.82% in the last 24 hours and up +40.22% over the past month. Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Previous Close:

$5.89

Open:

$5.76

24h Volume:

91,502

Relative Volume:

0.35

Market Cap:

$122.82M

Revenue:

Net Income/Loss:

$-57.59M

P/E Ratio:

-2.1313

EPS:

-2.6486

Net Cash Flow:

$-54.27M

1W Performance:

+4.33%

1M Performance:

+40.22%

6M Performance:

-44.13%

1Y Performance:

-46.71%

1-Day Range:

$5.37

$5.76

1-Week Range:

$5.15

$5.93

52-Week Range:

$3.35

$17.94

Aardvark Therapeutics Inc Stock (AARD) Company Profile

Name

Aardvark Therapeutics Inc

Sector

Healthcare (1115)

Industry

Biotechnology (621)

Phone

(858) 225-7696

Address

4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO

Employee

Twitter

Next Earnings Date

2026-05-13

Latest SEC Filings

AARD's Discussions on Twitter

Compare AARD vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AARD Aardvark Therapeutics Inc	5.63	128.50M	0	-57.59M	-54.27M	-2.6486
VRTX Vertex Pharmaceuticals Inc	426.44	108.54B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	711.31	75.59B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	782.00	50.22B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	294.95	40.45B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	315.66	32.51B	5.36B	287.73M	924.18M	2.5229

Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-02-26	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-02-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-02-26	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Mar-02-26	Downgrade	Stifel	Buy → Hold
Jan-28-26	Initiated	B. Riley Securities	Buy
Dec-23-25	Initiated	Oppenheimer	Outperform
Dec-12-25	Initiated	William Blair	Outperform
Dec-03-25	Initiated	Raymond James	Strong Buy
Nov-07-25	Initiated	BTIG Research	Buy
Sep-29-25	Initiated	Stifel	Buy
Jun-30-25	Initiated	H.C. Wainwright	Buy
Mar-10-25	Initiated	BofA Securities	Buy
Mar-10-25	Initiated	Cantor Fitzgerald	Overweight
Mar-10-25	Initiated	Morgan Stanley	Overweight
Mar-10-25	Initiated	RBC Capital Mkts	Outperform

View All

Aardvark Therapeutics Inc Stock (AARD) Latest News

08:02 AM

Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - marketscreener.com

08:02 AM

05:59 AM

Number of shareholders of Aardvark Therapeutics, Inc. – NASDAQ:AARD - TradingView

05:59 AM

May 01, 2026

AARD Forecast, Price Target & Analyst Ratings | AARDVARK THERAPEUTICS INC (NASDAQ:AARD) - ChartMill

May 01, 2026

Apr 28, 2026

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid - GlobeNewswire

Apr 28, 2026

Apr 26, 2026

Aardvark Therapeutics, Inc. (NASDAQ:AARD) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Apr 26, 2026

Why Aardvark Therapeutics just lost more than half its value - MSN

Apr 26, 2026

Apr 22, 2026

AARD (Aardvark Therapeutics Inc.) posts narrower Q4 2025 loss than expected, sending shares nearly 5 percent higher.Institutional Grade Picks - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 22, 2026

Aardvark Therapeutics Shares Plummet After Trial Halt - Intellectia AI

Apr 22, 2026

Repeat: Norsk Hydro: Reminder – Invitation to Hydro’s first quarter results 2026 - Weekly Voice

Apr 22, 2026

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman - ChartMill

Apr 22, 2026

Apr 17, 2026

AARD Stock Price and Chart — NASDAQ:AARD - TradingView

Apr 17, 2026

Apr 16, 2026

Aardvark (AARD) Stock Mega Cap Focus (Trend Weakens) 2026-04-16Expert Stock Picks - Cổng thông tin điện tử tỉnh Lào Cai

Apr 16, 2026

Aardvark Therapeutics, Inc. (NASDAQ:AARD) Sees Large Decline in Short Interest - MarketBeat

Apr 16, 2026

Apr 12, 2026

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman - GlobeNewswire Inc.

Apr 09, 2026

Apr 08, 2026